Nyxoah SA
Business
Nyxoah SA is a medical technology company developing and commercializing the Genio system, a CE-marked and FDA-approved hypoglossal neurostimulation therapy for moderate to severe obstructive sleep apnea. The company's lead product is a leadless, externally-powered neurostimulator implanted via a single-incision procedure that delivers bilateral nerve stimulation. Nyxoah markets the Genio system in Europe (Germany, Switzerland, Spain, Finland, Austria, England, Netherlands, Abu Dhabi) and began U.S. commercialization in September 2025 following FDA approval in August 2025. The company builds commercial infrastructure through direct sales teams focused on high-volume centers, clinical evidence generation, and reimbursement strategies tailored to each market.
Summary from 20-F filed 2026-03-26
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-90.08M |
| Total assets | $118.50M |
| Total liabilities | $69.34M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Nyxoah SA's CIK number?
Nyxoah SA's SEC CIK number is 0001857190 (1857190). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Nyxoah SA's SEC filings?
All of Nyxoah SA's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.